Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03618550
Title Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

Hodgkin's lymphoma


Doxorubicin + Gemcitabine + Pembrolizumab + Vinorelbine

Age Groups: child | senior | adult
Covered Countries USA

No variant requirements are available.